CDK4/6 inhibitors (e.g., palbociclib, ribociclib, and abemaciclib) are promising drugs for various cancers (Du et al., 2020), working by specifically inhibiting CDK4/6 proteins, blocking the transition from the G1 to the S phase of the cell cycle and preventing cancer cell progression (Álvarez-Fernández and Malumbres, 2020). This evidence concerns the gene CDK4 and cancer.